Are New Drug Development Platforms Leading Pharma Innovation?
The European Pharmaceutical Manufacturer site noted that increasingly, the business model for drug discovery and development is predicated on recouping costs barely manageable for first-world, affluent nations. In an effort to combat this trend, various stakeholders in the drug discovery ecosystem have been identifying and exploring novel models based
Comments Off on Are New Drug Development Platforms Leading Pharma Innovation? • Read this story »
More Articles
What’s Driving the Boom in Early Stage Biotech Funding?
The LabTech website noted that J&J Innovation is one of the many investors that are turning their gaze to the promise of early-stage research. J&J Innovation is following a strategy focusing on supporting ‘open innovation’, an approach that they believe could work where the traditional
Comments Off on What’s Driving the Boom in Early Stage Biotech Funding? • Read this story »
Revolutionary Thinking in Pharma
The PharmaPhorum website noted that reliance on outmoded operating procedures, outdated infrastructure and ways of working is one of the biggest threats facing pharma companies. To overcome this the Janssen company has established innovation centers in the major science hot-bed cities across the
Comments Off on Revolutionary Thinking in Pharma • Read this story »
Vetter Launches Open Innovation Challenge
The Pharmabiz website reported that Vetter Pharma International, a leading contract development and manufacturing organization, has launched the Open Innovation Challenge campaign to develop a future-focused and sustainable solutions for the injection of medicines. It is bringing together approximately
Comments Off on Vetter Launches Open Innovation Challenge • Read this story »
Open Minds for Open Innovation
The PMLive website noted that many large, successful organizations such as Apple and NASA are already embracing open innovation to stay at the top of their game. In healthcare, programs like 23andMe and PatientsLikeMe have demonstrated that this is a tangible tactic, despite the traditional need for
Comments Off on Open Minds for Open Innovation • Read this story »
AstraZeneca CEO Heralds New Era of Collaboration
The Cambridge Independent website reported that AstraZeneca CEO Pascal Soriot announced that the company’s advanced drug discovery robot, NiCoLA-B, will be housed in the biopharmaceutical company’s new £500million global research and development center, heralding a new era of openness and
Comments Off on AstraZeneca CEO Heralds New Era of Collaboration • Read this story »
Korean Drugmakers to Seek Global Partnerships
The Korea Herald website reported that South Korean pharmaceutical companies and global drugmakers came together to discuss new business partnerships and open innovation at this year’s Korea Pharma Associations Conference in Seoul. As one of the biggest pharma industry events of the year, the conference
Comments Off on Korean Drugmakers to Seek Global Partnerships • Read this story »
Collaborations Can Make UK a Pharma Leader
The Pharma Letter website reported that the move away from the older model of closed corporate research and development labs and towards collaborative working and open innovation is highlighted as in the R&D sourcebook from the Association of the British Pharmaceutical Industry (ABPI). “It is therefore
Comments Off on Collaborations Can Make UK a Pharma Leader • Read this story »
Opening Up Innovation
The pmlive website noted that the [pharma] industry is increasingly open to academic collaborations and alongside this a more radical step can be seen in pharma’s willingness to move beyond ‘not invented here’ and take part in ‘open innovation’ initiatives. The trend is
Comments Off on Opening Up Innovation • Read this story »
Deloitte: Open Innovation Success Rate 3 Times Higher Than In-house R&D
The Knowledge website reported that the knowledge intensity and speed of biotechnology has shifted the locus of innovation to a network rather than within any single firm. This is causing pharmaceutical firms to look for new ways to tap into innovative sources of drug development outside their organizational
Comments Off on Deloitte: Open Innovation Success Rate 3 Times Higher Than In-house R&D • Read this story »